Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Filings indexed 523 across all filing types
Latest filing 2020-02-14 Major Shareholding Noti…
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2020-02-14 English
SC 13G/A
Major Shareholding Notification
2020-02-13 English
SC 13G/A
Major Shareholding Notification
2020-02-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on changes in compensation for key executives and approval of bonuses by the Board of Directors. There is no financial statement or detailed financial performance data presented, nor is it an earnings release or annual report. The primary subject is changes in management compensation and related board approvals, which fits the category of Board/Management Information (MANG). The document is about management decisions and approvals rather than a full report or announcement of voting results or capital changes. Therefore, the appropriate classification is MANG with high confidence.
2019-12-20 English
PRIMARY DOCUMENT
Director's Dealing
2019-11-21 English
PRIMARY DOCUMENT
Director's Dealing
2019-11-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.